Simulations Plus

Executive with relevant expertise in multiple industries succeeds retiring CEO Walt Woltosz, who remains chairman of the board

Significant improvements support internal research activities through regulatory interactions

US FDA Continues Its Goal of Propelling Model-Based Drug Development Forward

Simulations Plus, Inc. (NASDAQ: SLP), the premier provider of simulation and modeling software and consulting services for all stages of pharmaceutical discovery and development, today announced that it will be distributing a one-time $1,000 discretionary cash bonus to each of its employees.

Simulations Plus, Inc. (NASDAQ: SLP) will be discussing their earnings results in their Q2 Earnings Call to be held on April 9, 2018, at 4:15 PM Eastern Time.

Board of Directors Announces Quarterly Dividend of $0.06 Per Share

FinancialBuzz.com News Commentary

Major update to preclinical and clinical trial data analysis software addresses user requests

Significant update of liver safety program includes performance and capability enhancements

Consolidated net income up 26.0%; diluted earnings per share increased 22.8%

Conference Call to be on Tuesday, January 9, 2018, at 4:15 PM ET

Presentations Canceled for Celsius Holdings, Inc., GSI Technology, Inc., PCM, Inc., Simulations-Plus, ADOMANI, Inc., HUTN, Inc., NanoVibronix, Inc. and WidePoint Corp.

New HTPK Simulation Module allows chemists to screen compound libraries using novel approach